Signify Health and Ardent Health Services Collaborate to Improve Healthcare Outcomes – Yahoo Finance

Ardent transitions from the BPCI-A program to join a 2023 Signify Health-supported ACO designed to achieve superior patient outcomes and success in managing total costs
DALLAS & NEW YORK & NASHVILLE, Tenn., December 14, 2022–(BUSINESS WIRE)–Signify Health, Inc. (NYSE: SGFY), a leading healthcare platform that leverages advanced analytics, technology and nationwide healthcare networks to create and power value-based payment programs, today announced an expansion of its relationship with Ardent Health Services, a premier provider of healthcare services with more than 200 sites of care across six states. A former participant in the Center for Medicare and Medicaid Innovation’s Bundled Payments for Care Improvement-Advanced (BPCI-A) program, Ardent will join a 2023 Signify-enabled accountable care organization (ACO) to implement care transformation, manage risk and provide high-quality, coordinated care for its Medicare patients.
Ardent’s affiliated network of facilities and physicians in New Mexico, Oklahoma, Texas, and Kansas will work together with independent providers in a collaborative ACO model to achieve the benefits of scale and to effectively manage risk. The strategic collaboration will support alignment with the Centers for Medicare & Medicaid Services’ (CMS) goal of having all Medicare beneficiaries enrolled in an accountable relationship by 2030.
"Ardent is proud of our success to date in value-based care, including the work we have done to transform our patient experience after discharge to achieve an over 26% reduction in our 90-day readmission rate and improve the clinical outcomes among participating patients," said Marty Bonick, President and CEO of Ardent Health Services. "We are excited to expand our partnership with Signify Health to bring our patients proven preventive and care management services that will help drive better health and improve the overall experience for both patients and care teams."
Earlier this year, Signify Health acquired Caravan Health, a leader in enabling sustainable ACO and population health programs. With this acquisition, Signify Health supports one of the largest networks of at-risk providers and offers one comprehensive platform to manage total cost of care. In 2020 and 2021, 100% of Signify Health’s collaborative ACO participants earned shared savings.
According to Tim Gronniger, Chief of Value-based Care Solutions, Signify Health, "CMS has stated that providers will soon be expected to move away from fee-for-service and take accountability for their cost of care. We are thrilled to work with Ardent Health Services to deliver the infrastructure needed to support their success with accountable care. Through our work together, Ardent’s Medicare patients will receive increased access to preventative and in-home services that can help to diminish health inequities and increase savings."
About Signify Health
Signify Health is a leading healthcare platform that leverages advanced analytics, technology, and nationwide healthcare provider networks to create and power value-based payment programs. Our mission is to build trusted relationships to make people healthier. Our solutions support value-based payment programs by aligning financial incentives around outcomes, providing tools to health plans and healthcare organizations designed to assess and manage risk and identify actionable opportunities for improved patient outcomes, coordination and cost-savings. Through our platform, we coordinate what we believe is a holistic suite of clinical, social, and behavioral services to address an individual’s healthcare needs and prevent adverse events that drive excess cost, all while shifting services towards the home. For more information on how we are taking health homeward, visit us at
About Ardent Health Services
Ardent Health Services invests in people, technology and communities. Through its subsidiaries, Ardent owns and operates 30 hospitals and nearly 200 sites of care in six states with more than 24,000 employees, including 1,200+ employed providers. With a focus on evidence-based practices to improve quality care and patient outcomes, 95% of eligible Ardent hospitals received a Leapfrog Hospital Safety Grade of A or B for Fall 2022, compared with 57% of all ranked U.S. hospitals. In 2022, Modern Healthcare recognized six Ardent entities as "Best Places to Work," marking the 14th consecutive year an Ardent facility was recognized. Based in Nashville, Tennessee, Ardent is owned by current and former members of Ardent’s management team; Equity Group Investments (EGI), a Chicago-based private investment firm; and Ventas, Inc. (NYSE: VTR), a publicly traded real estate investment trust.
View source version on
Lynn Shepherd,, (610) 613-7263
Rebecca Kirkham,, (615) 296.3635
Related Quotes
A "bruising" FDA meeting for Cytokinetics was actually a blessing in disguise, an analyst said Wednesday as CYTK stock surged.
Moderna could have a winner with its personalized cancer vaccine. But the company also faces big questions.
Kymera unveiled promising results for its skin-disease treatment on Wednesday, snagging interest from Sanofi and sending KYMR stock flying.
Yahoo Finance health correspondent Anjalee Khemlani joins the Live show to review Moderna and Merck shares following positive results seen in their joint cancer vaccine trial.
Chardan Capital Markets analyst Geulah Livshits now rates the biotech company at Neutral, down from Buy.
The FDA's Cardiovascular and Renal Drugs Advisory Committee voted 8-3 against the approval of Cytokinetics Incorporated's (NASDAQ: CYTK) heart failure drug, omecamtiv mecarbil. Adcomm members said the drug's potential benefits did not seem to outweigh its risks, with panel members raising concerns about its safety and limited efficacy. The company's application to the FDA was based on results from a late-stage study of over 8,000 patients. The drug met trial goals of reducing the risk of heart f
Moderna CEO Stéphane Bancel speaks with Yahoo Finance's Anjalee Khemlani about the company's MRNA skin cancer vaccine trial with Merck and the pipeline for producing cancer vaccines.
SELLAS Life Sciences Group Inc (NASDAQ: SLS) announced results from its ongoing dose-escalating Phase 1 study of GFH009 in patients with relapsed and/or refractory (r/r) hematologic malignancies. One patient treated with GFH009 in the 30 mg once-per-week cohort achieved a confirmed complete response (CR), which is the first CR reported in acute myeloid leukemia (AML) with any CDK9 inhibitor monotherapy. No minimal residual disease (MRD) was detected in this CR patient, and full neutrophil, plate
Is Merck stock a buy after Moderna said adding its cancer vaccine to Keytruda reduced the risk of relapse? Is MRK stock a buy now?
U.S. life sciences company Illumina Inc on Tuesday defended its $7.1 billion acquisition of biotech firm Grail Inc , pledging to keep selling its DNA sequencing services to other firms, as it seeks to head off a potential vote by U.S. antitrust regulators to kill the deal. The Federal Trade Commission, which enforces antitrust law, filed a complaint in March 2021 to stop Illumina's bid for its former subsidiary Grail. The agency cited concerns that Illumina, the dominant provider of DNA sequencing for multi-cancer early detection tests, might raise prices or refuse to keep selling to rivals of Grail, which is seeking to market a powerful test to diagnose many kinds of cancer from a single blood test.
Regeneron (REGN) releases positive initial data on two candidates – linvoseltamab and odronextamab at ASH.
(Reuters) -Eli Lilly and Co said on Tuesday it hopes to launch as many as five new treatments next year that could drive growth through the decade as it bets on multi-billion dollar markets for treating obesity and Alzheimer's disease. The drugmaker is spending heavily on marketing and research and development as it prepares for data release and potential approvals for two keenly watched drugs next year, donanemab for Alzheimer's and tirzepatide for obesity. The higher spending led Lilly to forecast 2023 profit below analysts' estimates and its shares fell about 1% to $363.59.
Eli Lilly said Tuesday it plans to advance its next-generation obesity treatment into final-phase testing, but LLY stock dipped on guidance.
Moderna unveiled promising results for its personalized cancer vaccine on Tuesday. The results sent Moderna shares soaring.
Cellectis S.A (NASDAQ: CLLS) highlighted updated clinical data on its Phase 1/2a BALLI-01 trial (evaluating UCART22) and on its Phase 1 AMELI-01 trial (evaluating UCART123). Compared to the last clinical update on BALLI-01 at ASH 2021, the presented data comes from five additional patients who received UCART22 at dose level 3 (DL3) 5×106 cells/kg after lymphodepletion with FCA. Evidence of UCART22 anti-tumor activity was observed in 60% (n=3) of the five patients. A patient experienced a durable
Bluebird Bio (NASDAQ: BLUE) stock got off to a roaring start on Monday, trouncing the S&P 500 index with a nearly 8% gain. The market was cheered by a clinical update and the potential for a new regulatory application in the near future. On Saturday at a healthcare conference, Bluebird presented recent data on its gene therapies for beta-thalassemia and sickle cell disease (SCD).
The shot combined with a Merck immunotherapy reduced the risk of relapse in people with skin cancer in a study, Moderna said.
The purchase of Horizon Therapeutics is the biggest this year by a major drugmaker seeking new sources of revenue to offset impending patent expiries.
Horizon Therapeutics PLC’s planned $27.8 billion sale to Thousand Oaks, California’s Amgen Inc. would put the West Coast biopharmaceutical giant in Montgomery County for the first time, though it’s not yet clear what the deal would mean for the combined company’s local real estate. The agreement, announced Monday, comes as Dublin-based Horizon builds a research and development hub in Rockville and roughly two years after it acquired Gaithersburg’s Viela Bio Inc. for $3 billion. The deal, first reported by the Wall Street Journal, would mark the industry's largest merger this year.
In this article, we will be taking a look at the 15 biggest diet/weight loss companies in the world. To skip our detailed analysis of these companies, you can go directly to see the 5 Biggest Diet/Weight Loss Companies in the World. Over the years, there has been a growth in popularity when it comes to […]


Leave a Comment